Clyde Bailey

Director of Bioinformatics

UAMS

Also affiliated: The Honourable Society of Lincoln's Inn (1987); Thomas Jefferson University (2012); University of Arkansas Medical Center (2016); University Medical Center Utrecht (2019); Sidney Kimmel Cancer Center (2012); Winthrop Rockefeller Foundation (2021–2025)

Faculty Researcher

14 h-index 95 pubs 1,960 cited

Research Areas

Biomedical Subjects

Links

ORCID Lab Website

OverviewAI-generated summary

Clyde Bailey's research focuses on multiple myeloma, investigating its underlying mechanisms and potential therapeutic strategies. His work includes examining the immune microenvironment's alterations in multiple myeloma and its precursor stages, as well as identifying specific gene expressions, such as NEK2, that may suppress T-cell immunity. Bailey also studies the predictive value of gene signatures for disease progression and explores the feasibility of outpatient stem cell transplantation for multiple myeloma patients, identifying risk factors for hospital admission. His collaborative efforts at the University of Arkansas for Medical Sciences involve extensive work with researchers like Fenghuang Zhan, John D. Shaughnessy, and Guido Tricot, evidenced by numerous shared publications. Bailey's scholarship metrics include an h-index of 14, 95 total publications, and 1,943 total citations.

Metrics

h-index: 14
Publications: 95
Citations: 1,960

Selected Publications

Long term follow up of multiple myeloma patients achieving MRD negativity at 10 <sup>-6</sup> . (2026)

Journal of Clinical Oncology DOI OpenAlex
Gene Expression–Based prediction of 1q, 1p, 13q, and 17p chromosome ploidy in newly diagnosed and paired relapsed myeloma and across the plasma cell dyscrasia spectrum (2025)

Blood DOI OpenAlex
Prognostic impact of focal lesion location and persistence in multiple myeloma: insights from serial PET/DWI imaging (2025)

Blood Advances 1 citation DOI OpenAlex
Polyclonal plasma cell (PolyPC) signature as a key indicator for predicting the progression of MGUS to multiple myeloma (2025)

Cancer Biomarkers 1 citation DOI OpenAlex
Long-Term Follow-Up of Patients With Multiple Myeloma Treated on Earlier Total Therapy Protocols (2025)

JAMA Oncology 6 citations DOI OpenAlex
Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma (2024)

Blood Advances 6 citations DOI OpenAlex
Minimal Residual Disease (MRD) Status and Its Impact on Clinical Outcome Is Highly Variable in Multiple Myeloma and Dependent on Molecular Subgroups Defined By Gene Expression Profiling (GEP) (2024)

Blood DOI OpenAlex
Identification of Risk Factors for Myeloma Progression in African American Patients (2024)

Blood DOI OpenAlex
The Low-Bone (LB) Subtype of Multiple Myeloma Exhibits an Inferior Outcome in African Americans (2024)

Blood DOI OpenAlex
Multi-Omics Reveal Immune Microenvironment Alterations in Multiple Myeloma and Its Precursor Stages (2024)

Blood 1 citation DOI OpenAlex
Of Seven Molecular Subtypes in MGUS the Low Bone Disease (LB) Subtype Exhibits Resistance to Multiple Myeloma Progression (2024)

Blood DOI OpenAlex
Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages (2024)

Blood Cancer Journal 35 citations DOI OpenAlex
Second primary malignancies after tandem autologous hematopoietic stem cell transplantation for multiple myeloma (2024)

American Journal of Hematology 3 citations DOI OpenAlex
CLO24-090: Demographics and Outcomes of Autologous Stem Cell Transplant Among IgD Multiple Myeloma Patients (2024)

Journal of the National Comprehensive Cancer Network DOI OpenAlex
A Risk Stratification System in Myeloma Patients with Autologous Stem Cell Transplantation (2024)

Cancers 4 citations DOI OpenAlex